The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
MiR‐129‐5p promotes docetaxel resistance in prostate cancer by down‐regulating CAMK2N1 expression
Abstract
This study focuses on the effect of miR‐129‐5p on docetaxel‐resistant (DR) prostate cancer (PC a) cells invasion, migration and apoptosis. In our study, the expression of CAMK 2N1 was assessed by qRT‐PCR in PC a patient tissues and cell lines including PC‐3 and PC‐3‐DR. Cells transfected with miR‐129‐5p mimics, inhibitor, CAMK 2N1 or negative controls (NC) were used to interrogate their effects on DR cell invasions, migrations and apoptosis during docetaxel (DTX) treatments. The apoptosis rate of the PC a cells was validated by flow cytometry. Relationships between miR‐129‐5p and CAMK 2N1 levels were identified by qRT‐PCR and dual‐luciferase reporter assay. CAMK 2N1 was found to be down‐expressed in DR PC a tissue sample, and low levels of CAMK 2N1 were correlated with high docetaxel resistance and clinical prediction of poor survival. CAMK 2N1 levels were decreased in DR PC a cells treated with DXT. We further explored that up‐regulation of miR‐129‐5p could promote DR PC a cells viability, invasion and migration but demote apoptosis. Involved molecular mechanism studies revealed that miR‐129‐5p reduced downstream CAMK 2N1 expression to further impact on chemoresistance to docetaxel of PC a cells, indicating its vital role in PC a docetaxel resistance. Our findings revealed that miR‐129‐5p contributed to the resistance of PC‐3‐DR cells to docetaxel through suppressing CAMK 2N1 expression, and thus targeting miR‐129‐5p may provide a novel therapeutic approach in sensitizing PC a to future docetaxel treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Decreased levels of miR-129-5p have been observed in various cancers and low miR-129-5p levels have been associated with a reduced efficacy of chemotherapy because miR-129-5p was found to control various genes linked to cell proliferation [78, 79].”
From A role for astrocytic miR-129-5p in frontotemporal dementia (2025) · cites this paper as [78]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Wang, C., Li, N., Liu, X., Zheng, Y., & Cao, X. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800436200 · Cited by 70
RetractedLiu, X., Wang, Y., & Zhao, J. (2017) · Oncology Reports · doi:10.3892/or.2017.5997 · Cited by 15
Retracted5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332 · cited 1×
“rouracil acts as thymidylate synthase inhibitor blocking synthesis of the pyrimidine thymidine which is required for DNA replication.(26,27) Therefore, the promoting function of miR‐129 in chemoresistance could be highly drug‐specific, which needs further studies.”
BackgroundDocetaxel: A Review of its Use in Metastatic Breast Cancer
Lyseng-Williamson, K. A., & Fenton, C. (2005) · Drugs · doi:10.2165/00003495-200565170-00007 · Cited by 225
Bhatnagar, N., Li, X., Padi, S. K. R., Zhang, Q., Tang, M.-S., & Guo, B. (2010) · Cell Death & Disease · doi:10.1038/cddis.2010.85 · Cited by 203
microRNA expression profile in undifferentiated gastric cancer
Ishiguro (1992) · International Journal of Oncology · doi:10.3892/ijo_00000179 · Cited by 203
miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer
Karaayvaz, M., Zhai, H., & Ju, J. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.193 · Cited by 191
Epigenetic regulation of miR‐34b and miR‐129 expression in gastric cancer
Tsai, K., Wu, C., Hu, L., Li, S., Liao, Y., Lai, C., Kao, H., Fang, W., Huang, K., Chan, W., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25919 · Cited by 183
Self-citationMicroRNA expression profile in undifferentiated gastric cancer
堅田, 武. (2010) · Medical Entomology and Zoology · Cited by 125
Expression profiling of micro-RNAs in human esophageal squamous cell carcinoma using RT-PCR
Ogawa, R., Ishiguro, H., Kuwabara, Y., Kimura, M., Mitsui, A., Katada, T., Harata, K., Tanaka, T., & Fujii, Y. (2009) · Medical Molecular Morphology · doi:10.1007/s00795-009-0443-1 · Cited by 118
Cited by
Hashemi, M., Zandieh, M. A., Talebi, Y., Rahmanian, P., Shafiee, S. S., Nejad, M. M., Babaei, R., Sadi, F. H., Rajabi, R., Abkenar, Z. O., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114392 · Cited by 117
RetractedA role for astrocytic miR-129-5p in frontotemporal dementia
Kaurani, L., Pradhan, R., Schröder, S., Burkhardt, S., Schuetz, A.-L., Krüger, D. M., Pena, T., Heutink, P., Sananbenesi, F., & Fischer, A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03338-y · Cited by 10
Metadata
- Authors
- Wu, C., Miao, C., Tang, Q., Zhou, X., Xi, P., Chang, P., Hua, L., & Ni, H.
- Affiliations
- Department of Urology The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China
- Department of Urology People's Hospital of Dongtai City Dongtai Jiangsu China
- ORCID
- Hua, Lixin
- Venue
- Journal of Cellular and Molecular Medicine
- Publisher
- Wiley
- Published
- 2019-12-26
- Volume
- 24
- Issue
- 3
- Pages
- 2098-2108
- ISSN
- 1582-1838
- 1582-4934
- PMC
- PMC7011149
- Cited by
- 28
- References
- 28
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.